Business ❯ Corporate Governance
Resignation Leadership Changes CEO Financial Reporting CEO Resignation Leadership CFO Board of Directors Succession Planning Whistleblowing Employee Relations Employment Contracts Healthcare Industry Dismissals Financial Performance Security Measures Public Relations Leadership Challenges Strategic Planning CEO Roles Legal Issues Legal Disputes CEO Actions CEO Transition Dismissal Ethics Compensation Compensation Packages Scandals Healthcare Executives CEO Changes Corporate Structure Conflicts of Interest CFO Transition Whistleblower Policies Health Issues Crisis Management Human Resources Security Management Insider Trading Corporate Crime Firing Corporate Ethics Performance Evaluation Accountability Corporate Security Retirement Personnel Changes Decision Making Contract Extensions Workforce Management Leadership Issues Contractual Agreements Interim CEO Terminations CEO and COO Roles Suspension Compensation Policies Company Operations Financial Statements Leadership Transition Communication CEO Contracts Firing Practices Bank Executives Executive Turnover Angela Titzrath Interim Leadership Dual Loyalties Appointments Employee Departures Strategic Changes Layoffs Career Transitions Cost Cutting Director Roles Workplace Relationships Corporate Misconduct Fraudulent Practices Fiduciary Duties Sports Teams Financial Practices Contracts Severance Agreements NHIDCL Resignations CEO Appointment CFO Insights Financial Directors Telecommunications Finance Talent Acquisition Strategic Partnerships CEO Compensation Company Performance Employment Agreements Performance Issues CEO Issues Ethics in Business Shareholder Relations
Board investigators found excess Nexplanon shipments to U.S. wholesalers from 2022 to 2025 that made sales statements inaccurate.